These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 22289353)

  • 21. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An anti-murine CD3 monoclonal antibody with a low affinity for Fc gamma receptors suppresses transplantation responses while minimizing acute toxicity and immunogenicity.
    Alegre ML; Tso JY; Sattar HA; Smith J; Desalle F; Cole M; Bluestone JA
    J Immunol; 1995 Aug; 155(3):1544-55. PubMed ID: 7636216
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cloning and characterization of novel tumor-targeting immunocytokines based on murine IL7.
    Pasche N; Woytschak J; Wulhfard S; Villa A; Frey K; Neri D
    J Biotechnol; 2011 Jun; 154(1):84-92. PubMed ID: 21527292
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
    Khawli LA; Hu P; Epstein AL
    Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression, engineering and characterization of the tumor-targeting heterodimeric immunocytokine F8-IL12.
    Sommavilla R; Pasche N; Trachsel E; Giovannoni L; Roesli C; Villa A; Neri D; Kaspar M
    Protein Eng Des Sel; 2010 Aug; 23(8):653-61. PubMed ID: 20551083
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
    Lu C; Hassan HT
    Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The dose-dependent tumor targeting of antibody-IFNγ fusion proteins reveals an unexpected receptor-trapping mechanism in vivo.
    Hemmerle T; Neri D
    Cancer Immunol Res; 2014 Jun; 2(6):559-67. PubMed ID: 24795141
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibody targeted drugs as cancer therapeutics.
    Schrama D; Reisfeld RA; Becker JC
    Nat Rev Drug Discov; 2006 Feb; 5(2):147-59. PubMed ID: 16424916
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fully human, HLA-DR-specific monoclonal antibodies efficiently induce programmed death of malignant lymphoid cells.
    Nagy ZA; Hubner B; Löhning C; Rauchenberger R; Reiffert S; Thomassen-Wolf E; Zahn S; Leyer S; Schier EM; Zahradnik A; Brunner C; Lobenwein K; Rattel B; Stanglmaier M; Hallek M; Wing M; Anderson S; Dunn M; Kretzschmar T; Tesar M
    Nat Med; 2002 Aug; 8(8):801-7. PubMed ID: 12101408
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of targeted therapies for B-cell non-Hodgkin lymphoma and multiple myeloma.
    Hernandez-Ilizaliturri FJ; Gowda A; Czuczman MS
    Clin Adv Hematol Oncol; 2004 Sep; 2(9):606-18. PubMed ID: 16163245
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adenovirus-mediated intratumoral lymphotactin gene transfer potentiates the antibody-targeted superantigen therapy of cancer.
    Wang Q; Yu H; Zhang L; Ju D; Pan J; Xia D; Yao H; Zhang W; Wang J; Cao X
    J Mol Med (Berl); 2002 Sep; 80(9):585-94. PubMed ID: 12226740
    [TBL] [Abstract][Full Text] [Related]  

  • 32. TRU-016, a humanized anti-CD37 IgG fusion protein for the potential treatment of B-cell malignancies.
    Robak T; Robak P; Smolewski P
    Curr Opin Investig Drugs; 2009 Dec; 10(12):1383-90. PubMed ID: 19943209
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeted drug delivery using immunoconjugates: principles and applications.
    Pasquetto MV; Vecchia L; Covini D; Digilio R; Scotti C
    J Immunother; 2011; 34(9):611-28. PubMed ID: 21989410
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution.
    Tzeng A; Kwan BH; Opel CF; Navaratna T; Wittrup KD
    Proc Natl Acad Sci U S A; 2015 Mar; 112(11):3320-5. PubMed ID: 25733854
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Advances in antibody-directed enzyme prodrug therapy.
    Sharma SK; Bagshawe KD; Begent RH
    Curr Opin Investig Drugs; 2005 Jun; 6(6):611-5. PubMed ID: 15997480
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improving the efficacy of antibody-interleukin 2 fusion proteins by reducing their interaction with Fc receptors.
    Gillies SD; Lan Y; Lo KM; Super M; Wesolowski J
    Cancer Res; 1999 May; 59(9):2159-66. PubMed ID: 10232603
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CD20-targeted therapy: a breakthrough in the treatment of non-Hodgkin's lymphoma.
    van Meerten T; Hagenbeek A
    Neth J Med; 2009; 67(7):251-9. PubMed ID: 19687518
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular engineering of short half-life small peptides (VIP, αMSH and γ₃MSH) fused to latency-associated peptide results in improved anti-inflammatory therapeutics.
    Vessillier S; Adams G; Montero-Melendez T; Jones R; Seed M; Perretti M; Chernajovsky Y
    Ann Rheum Dis; 2012 Jan; 71(1):143-9. PubMed ID: 21998117
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antibody-cytokine fusion proteins for cancer immunotherapy: an update on recent developments.
    Müller D
    BioDrugs; 2014 Apr; 28(2):123-31. PubMed ID: 24018469
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunocytokines for cancer treatment: past, present and future.
    Neri D; Sondel PM
    Curr Opin Immunol; 2016 Jun; 40():96-102. PubMed ID: 27060634
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.